AI-Powered ECG could spot hidden heart disease faster
NCT ID NCT05557162
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether an artificial intelligence (AI) tool could help doctors detect cardiac amyloidosis, a rare but serious heart condition, earlier using standard ECG tests. Over 20,000 patients were involved, with some doctors using the AI-enhanced ECG and others continuing usual care. The goal was to see if the AI tool leads to more and earlier diagnoses.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
20,143 people
The number who actually took part.
- Started
-
Jun 2023
- Finished
-
Jul 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Mayo Clinic cardiology or hematology providers who care for adult patients * Mayo Clinic providers who consent to participate on this study Exclusion Criteria: \- None
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cardiac amyloidosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Mayo Clinic Health System - Eau Claire
Eau Claire, Wisconsin, 54701, United States
-
Mayo Clinic in Arizona
Scottsdale, Arizona, 85259, United States
-
Mayo Clinic in Florida
Jacksonville, Florida, 32224, United States
-
Mayo Clinic in Rochester
Rochester, Minnesota, 55905, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can AI read fused PET and MRI scans to forecast survival in a rare heart disease?
- Can a single scan reveal hidden amyloid deposits across the body?
- Heart ultrasound may spot a rare heart disease earlier
- A sharper eye on amyloid: could quantitative scans revolutionize cardiac monitoring?
- Can a new PET tracer light up amyloid in the heart?
- Liver clues: a new way to stage heart amyloidosis?